Skip to main content Accessibility help
×
Home
  • Print publication year: 2014
  • Online publication date: October 2014

Chapter 27 - Clozapine

from Section 4 - Treatment

References

Altamura, C., Bobo, W. V., & Meltzer, H. Y. (2007). Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. International Clinical Psychopharmacology, 22, 249–267.
Axelsson, R., & Lagerkvist-Briggs, M. (1992). Factors predicting suicide in psychotic patients. European Archives of Psychiatry and Clinical Neuroscience, 241, 259–266.
Beasley, C. M. Jr, Tollefson, G. D., & Tran, P. V. (1997). Efficacy of olanzapine: an overview of pivotal clinical trials. Journal of Clinical Psychiatry, 58(Suppl 10), 7–12.
Bleuler, M. (1976). An approach to a survey of research results on schizophrenia. Schizophrenia Bulletin, 2, 356–357.
Bushe, C. J., Taylor, M., & Haukka, J. (2010). Mortality in schizophrenia: a measurable clinical endpoint. Journal of Psychopharmacology, 24(4 Suppl), 17–25.
Caldwell, C. B., & Gottesman, I. I. (1990). Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophrenia Bulletin, 16, 571–589.
Cormac, I., Brown, A., Creasey, S., Ferriter, M., & Huckstep, B. (2010).A retrospective evaluation of the impact of total smoking cessation on psychiatric inpatients taking clozapine. Acta Psychiatrica Scandinavica, 121(5), 393–397.
De Hert, M., Correll, C. U., & Cohen, D. (2010). Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophrenia Research, 117(1), 68–74.
Hall, R. L., Smith, A. G., & Edwards, J. G. (2003). Haematological safety of antipsychotic drugs. Expert Opinion on Drug Safety, 2, 395–399.
Hennen, J., & Baldessarini, R. J. (2005). Suicidal risk during treatment with clozapine: a meta-analysis. Schizophrenia Research, 73(2–3), 139–145.
Hoang, U., Goldacre, M. J., & Stewart, R. (2013). Avoidable mortality in people with schizophrenia or bipolar disorder in England. Acta Psychiatrica Scandinavica, 127(3), 195–201.
Horvitz-Lennon, M., Donohue, J. M., Domino, M. E., & Norman, S -L. T. (2009). Improving quality and diffusing best practices: The case of schizophrenia. Health Affairs, 28(3), 701–712.
Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45(9), 789–796.
Knittel, D., Munn, G., & Simmer, E. (2008). Prodromal psychosis as an etiology of suicide: a case report and review of the literature. American Journal of Forensic Medicine and Pathology, 29(3), 238–241.
Leadbetter, R., Shutty, M., Pavalonis, D., et al. (1992). Clozapine-induced weight gain: prevalence and clinical relevance. American Journal of Psychiatry, 149(1), 68–72.
Masoudzadeh, A., & Khalilian, A. R. (2007). Comparative study of clozapine, electroshock and the combination of ECT with clozapine in treatment-resistant schizophrenic patients. Pakistani Journal of Biological Sciences, 10(23), 4287–4290.
Meltzer, H. Y. (2005). Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine. Journal of Clinical Psychiatry, 66(4), 530–533.
Meltzer, H. Y. (2012). Clozapine: balancing safety with superior antipsychotic efficacy. Clinical Schizophrenia and Related Psychoses, 6(3), 134–144.
Meltzer, H. Y., & Okayli, G. (1995). Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. American Journal of Psychiatry, 152, 183–190.
Meltzer, H. Y., Alphs, L., Green, A. I., et al., for the International Suicide Prevention Trial Study Group. (2003a). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry, 60, 82–89.
Meltzer, H. Y., Perry, E., & Jayathilake, K. (2003b). Clozapine-induced weight gain predicts improvement in psychopathology. Schizophrenia Research, 59, 19–27.
Merrill, D. B., Dec, G. W., & Goff, D. C. (2005). Adverse cardiac effects associated with clozapine. Journal of Clinical Psychopharmacology, 25(1), 32–41.
Modestin, J., Dal Pian, D., & Agarwalla, P. (2005). Clozapine diminishes suicidal behavior: a retrospective evaluation of clincial records. Journal of Clinical Psychiatry, 66, 534–538.
Muller-Siecheneder, F., Muller, M. J., Hillert, A., et al. (1998). Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. Journal of Clinical Psychopharmacology, 18, 111–120.
Munro, J., O’Sullivan, D., Andrews, C., et al. (1999). Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. The British Journal of Psychiatry, 175, 576–580.
Palmer, D. D., Henter, I. D., & Wyatt, R. J. (1999). Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia?Journal of Clinical Psychiatry 60(Suppl 2): 100–103.
Palmer, B. A., Pankrantz, V. S., & Bostwick, J. M. (2005). The lifetime risk of suicide in schizophrenia. Archives of General Psychiatry, 62, 247–253.
Pompili, M., Lester, D., Dominici, G., et al. (2013). Indications for electroconvulsive treatment in schizophrenia: A systematic review. Schizophrenia Research, 146, 1–9.
Reid, W. H., Mason, M., & Hogan, T. (1998). Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatric Services, 49, 1029–1033.
Siris, S. G., Bermanzohn, P. C., Mason, E. D., & Shuwall, M. D. (1994). Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. Archives of General Psychiatry, 51(2), 109–115.
Spivak, B., Roitman, S., Vered, Y., et al. (1998). Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clinical Neuropharmacology, 21, 245–250.
Thomas, S. H., Drici, M. D., Hall, G. C., et al. (2010). Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatrica Scandinavica, 122(5), 345–355.
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., et al. (2009). 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet, 374(9690), 620–627.
Tiwari, A. K., Need, A. C., Lohoff, F. W., et al. (2013). Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis. Molecular Psychiatry. 2013 Jun 11. doi: 10.1038/mp. 2013.74. [Epub ahead of print].
Tran, P. V., Hamilton, S. H., Kuntz, A. J., et al. (1997). Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology, 17, 407–418.
Urichuk, L., Prior, T. I., Dursun, S., & Baker, G. (2008). Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Current Drug Metabolism, 9(5), 410–418.
Walker, A. M., Lanza, L. L., Arellano, F., & Rothman, K. J. (1997). Mortality in current and former users of clozapine. Epidemiology, 8, 671–677.
Warner, B., & Hoffmann, P. (2002). Investigation of the potential of clozapine to cause torsade de pointes. Adverse Drug Reactions Toxicology Review, 21(4),189–203.
Weiner, E., Conley, R. R., Ball, M. P., et al. (2010). Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology, 35(11), 2274–2283.
Yağcioğlu, A. E. A., Akdede, B. B. K., Turgut, T. I., et al. (2005). A double-blind controlled study adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry, 66, 63–72.
Zhu, B., Ascher-Svanum, H., Faries, D. E., et al. (2008). Costs of treating patients with schizophrenia who have illness-related crisis events. BMC Psychiatry, 8, 72.